Hanjong Ahn

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1248792/publications.pdf

Version: 2024-02-01

236612 264894 2,997 194 25 42 citations h-index g-index papers 196 196 196 3985 times ranked docs citations citing authors all docs

#	Article	IF	CITATIONS
1	Establishment of Prospective Registry of Active Surveillance for Prostate Cancer: The Korean Urological Oncology Society Database. World Journal of Men?s Health, 2023, 41, 110.	1.7	1
2	Association Between Sarcopenia and Survival of Patients with Organ-Confined Renal Cell Carcinoma after Radical Nephrectomy. Annals of Surgical Oncology, 2022, 29, 2473-2479.	0.7	12
3	Enzalutamide in Chemotherapy-NaÃ ⁻ ve Metastatic Castration-Resistant Prostate Cancer: An Asian Multiregional, Randomized Study. Advances in Therapy, 2022, 39, 2641-2656.	1.3	7
4	Differential contribution of the factors determining long-term renal function after partial nephrectomy over time. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 196.e15-196.e20.	0.8	6
5	Serum Testosterone Level as Possible Predictive Marker for Prognosis in Metastatic Castration-Resistant Prostate Cancer Patients Treated With Enzalutamide. The Korean Journal of Urological Oncology, 2021, 19, 60-69.	0.1	O
6	Biopsy-detected Gleason grade 5 tumor is an additional prognostic factor in metastatic hormone-sensitive prostate cancer. Journal of Cancer Research and Clinical Oncology, 2021, , 1.	1.2	1
7	Validation of the European association of urology biochemical recurrence risk groups after radical prostatectomy in an Asian cohort and suggestions for refinement. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 298.e1-298.e6.	0.8	6
8	Impact of preoperative chemotherapy on pathologic nodal status in muscle-invasive bladder cancer: optimal lymphadenectomy in the preoperative chemotherapy era. Journal of Cancer Research and Clinical Oncology, $2021, 1.$	1.2	0
9	Salvage hypofractionated accelerated versus standard radiotherapy for the treatment of biochemical recurrence after radical prostatectomy (SHARE): the protocol of a prospective, randomized, open-label, superiority, multi-institutional trial. Trials, 2021, 22, 728.	0.7	1
10	ASO Visual Abstract: Association Between Sarcopenia and the Survival of Patients with Organ-Confined Renal Cell Carcinoma After Radical Nephrectomy. Annals of Surgical Oncology, 2021, , 1.	0.7	1
11	Value of clinical parameters and MRI with PI-RADS _{V2} in predicting seminal vesicle invasion of prostate cancer. Scandinavian Journal of Urology, 2021, 55, 17-21.	0.6	9
12	Risk Factors Leading to Radical Cystectomy in Patients Who Had Undergone Nephroureterectomy. The Korean Journal of Urological Oncology, 2021, 19, 271-280.	0.1	0
13	Utility of Urinalysis as a Follow-up Surveillance Tool in Nonmuscle Invasive Bladder Cancer. The Korean Journal of Urological Oncology, 2021, 19, 244-251.	0.1	O
14	Construction of a Retrospective Cohort to Observe 10-Year Urologic Cancer Treatment Trends at the Biggest Medical Center of South Korea. The Korean Journal of Urological Oncology, 2021, 19, 232-243.	0.1	1
15	Gemcitabine plus carboplatin versus gemcitabine plus oxaliplatin in cisplatin-unfit patients with advanced urothelial carcinoma: a randomised phase II study (COACH, KCSG GU10-16). European Journal of Cancer, 2020, 127, 183-190.	1.3	9
16	Utility of Multiparametric Magnetic Resonance Imaging With PI-RADS, Version 2, in Patients With Prostate Cancer Eligible for Active Surveillance: Which Radiologic Characteristics Can Predict Unfavorable Disease?. Clinical Genitourinary Cancer, 2020, 18, 50-55.	0.9	5
17	Phase I/IIa trial of androgen deprivation therapy, external beam radiotherapy, and stereotactic body radiotherapy boost for high-risk prostate cancer (ADEBAR). Radiation Oncology, 2020, 15, 234.	1.2	5
18	Clinical Evaluation of (4S)-4-(3-[18F]Fluoropropyl)-L-glutamate (18F-FSPG) for PET/CT Imaging in Patients with Newly Diagnosed and Recurrent Prostate Cancer. Clinical Cancer Research, 2020, 26, 5380-5387.	3.2	15

#	Article	IF	CITATIONS
19	Association of Bacillus Calmette–Guerin shortages with bladder cancer recurrence: A single-center retrospective study. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 851.e11-851.e17.	0.8	8
20	Percent tumor volume vs American Joint Committee on Cancer staging system subclassification for predicting biochemical recurrence in patients with pathologic T2 prostate cancer. Journal of Cancer Research and Clinical Oncology, 2020, 146, 537-543.	1.2	6
21	Surgical details and renal function change after robotâ€assisted partial nephrectomy. International Journal of Urology, 2020, 27, 457-462.	0.5	6
22	Risk of dementia and Parkinson's disease in patients treated with androgen deprivation therapy using gonadotropin-releasing hormone agonist for prostate cancer: A nationwide population-based cohort study. PLoS ONE, 2020, 15, e0244660.	1.1	5
23	The Use of Gonadotropin-Releasing Hormone Agonist Does Not Affect the Development of Cardiovascular Disease in Prostate Cancer Patients: a Nationwide Population-Based Cohort Study. Journal of Korean Medical Science, 2020, 35, e47.	1.1	4
24	Enzalutamide in chemotherapy-naive patients with metastatic castration-resistant prostate cancer: A retrospective Korean multicenter study in a real-world setting. Investigative and Clinical Urology, 2020, 61, 19.	1.0	6
25	Cause of Mortality After Radical Prostatectomy and the Impact of Comorbidity in Men with Prostate Cancer: A Multi-Institutional Study in Korea. Cancer Research and Treatment, 2020, 52, 1242-1250.	1.3	0
26	Title is missing!. , 2020, 15, e0244660.		0
27	Title is missing!. , 2020, 15, e0244660.		0
28	Title is missing!. , 2020, 15, e0244660.		0
29	Title is missing!. , 2020, 15, e0244660.		O
30	The impact on oncological outcomes after radical prostatectomy for prostate cancer of converting soft tissue margins at the apex and bladder neck from tumour-positive to -negative. BJU International, 2019, 123, 811-817.	1.3	8
31	The small molecule WNT/ \hat{l}^2 -catenin inhibitor CWP232291 blocks the growth of castration-resistant prostate cancer by activating the endoplasmic reticulum stress pathway. Journal of Experimental and Clinical Cancer Research, 2019, 38, 342.	3.5	46
32	Dihydrotestosterone promotes kidney cancer cell proliferation by activating the STAT5 pathway via androgen and glucocorticoid receptors. Journal of Cancer Research and Clinical Oncology, 2019, 145, 2293-2301.	1.2	12
33	Impact of lymph node dissection in radical cystectomy for bladder cancer: How many vs how far?. Surgical Oncology, 2019, 30, 109-116.	0.8	15
34	Adjuvant Treatments for Advanced Stage, Non-metastatic Upper Tract Urothelial Carcinoma: A Multicenter Study. International Journal of Radiation Oncology Biology Physics, 2019, 104, 819-827.	0.4	12
35	Integrity of the Urethral Sphincter Complex, Nerve-sparing, and Long-term Continence Status after Robotic-assisted Radical Prostatectomy. European Urology Focus, 2019, 5, 823-830.	1.6	33
36	Prognosis of carcinoma in situ according to the presence of papillary bladder tumors after bacillus Calmette–Guérin immunotherapy. Journal of Cancer Research and Clinical Oncology, 2019, 145, 2131-2140.	1.2	5

#	Article	IF	CITATIONS
37	Adjuvant chemotherapy versus observation after radical cystectomy in patients with node-positive bladder cancer. Scientific Reports, 2019, 9, 8305.	1.6	10
38	Time to biochemical relapse after radical prostatectomy and efficacy of salvage radiotherapy in patients with prostate cancer. International Journal of Clinical Oncology, 2019, 24, 1238-1246.	1.0	7
39	Elective pelvic irradiation in prostate cancer patients with biochemical failure following radical prostatectomy: A propensity score matching analysis. PLoS ONE, 2019, 14, e0215057.	1.1	8
40	Robotâ€assisted partial nephrectomy is associated with early recovery of renal function: Comparison of open, laparoscopic, and robotâ€assisted partial nephrectomy using DTPA renal scintigraphy. Journal of Surgical Oncology, 2019, 119, 1016-1023.	0.8	15
41	Taxane-based Chemotherapy Induced Androgen Receptor Splice Variant 7 in Patients with Castration-Resistant Prostate Cancer: A Tissue-based Analysis. Scientific Reports, 2019, 9, 16794.	1.6	7
42	Importance of androgen-deprivation therapy during enzalutamide treatment in men with metastatic castration-resistant prostate cancer following chemotherapy: results from retrospective, multicenter data. Prostate Cancer and Prostatic Diseases, 2019, 22, 150-158.	2.0	6
43	Induction Chemotherapy Followed by Surgery Versus Upfront Radical Cystectomy in Patients With Clinically Node-positive Muscle-invasive Bladder Cancer. Clinical Genitourinary Cancer, 2019, 17, e420-e428.	0.9	6
44	Simple risk assessment in prostate cancer patients treated with primary androgen deprivation therapy: The Korean Cancer Study of the Prostate risk classification. International Journal of Urology, 2019, 26, 62-68.	0.5	8
45	Association of Muscle Mass with Survival after Radical Prostatectomy in Patients with Prostate Cancer. Journal of Urology, 2019, 202, 525-532.	0.2	28
46	Gemcitabine plus carboplatin versus gemcitabine plus oxaliplatin in cisplatin unfit patients with advanced urothelial carcinoma: A randomized phase II study (COACH, KCSG GU10-16) Journal of Clinical Oncology, 2019, 37, 4534-4534.	0.8	1
47	The author's reply: Changes in health-related quality of life after radical prostatectomy for prostate cancer: A longitudinal cohort study in Korea. Investigative and Clinical Urology, 2019, 60, 224.	1.0	0
48	Gemcitabine-carboplatin (GCb) versus gemcitabine-oxaliplatin (GemOx) in cisplatin un-fit advanced urothelial carcinoma: Randomized phase II study (COACH Study) Journal of Clinical Oncology, 2019, 37, 355-355.	0.8	0
49	Reply by Authors. Journal of Urology, 2019, 202, 531-532.	0.2	O
50	Factors contributing to treatment outcomes of postâ€prostatectomy incontinence surgery for the selection of the proper surgical procedure for individual patients: A singleâ€center experience. Neurourology and Urodynamics, 2018, 37, 1978-1987.	0.8	10
51	Oncological effect of palliative transurethral resection of the prostate in patients with advanced prostate cancer: a propensity score matching study. Journal of Cancer Research and Clinical Oncology, 2018, 144, 751-758.	1.2	11
52	Androgen deprivation therapy during and after post-prostatectomy radiotherapy in patients with prostate cancer: a case control study. BMC Cancer, 2018, 18, 271.	1.1	3
53	Stereotactic body-radiotherapy boost dose of 18 Gy vs 21 Gy in combination with androgen-deprivation therapy and whole-pelvic radiotherapy for intermediate- or high-risk prostate cancer: a study protocol for a randomized controlled, pilot trial. Trials, 2018, 19, 212.	0.7	4
54	Discrimination of local recurrence after radical prostatectomy: valueÂof diffusion-weighted magnetic resonance imaging. Prostate International, 2018, 6, 12-17.	1.2	8

#	Article	IF	CITATIONS
55	Patterns of Recurrence After Salvage Radiotherapy Encompassing Pelvic Lymphatics in Men with High-risk Prostate Cancer. Anticancer Research, 2018, 38, 6579-6584.	0.5	2
56	Does epithelioid angiomyolipoma have poorer prognosis, compared with classic angiomyolipoma?. Investigative and Clinical Urology, 2018, 59, 357.	1.0	16
57	Prognostic factors of oncologic outcomes in metastatic chemotherapy-naÃ-ve castration-resistant prostate cancer treated with enzalutamide in actual clinical practice in East Asia. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 401.e11-401.e18.	0.8	9
58	Prognostic Factors Related to Recurrence-Free Survival for Primary Carcinoma in situ of the Bladder after Bacillus Calmette-GuÃ@rin: A Retrospective Study. Urologia Internationalis, 2018, 101, 269-276.	0.6	11
59	Changes in health-related quality of life after radical prostatectomy for prostate cancer: A longitudinal cohort study in Korea. Investigative and Clinical Urology, 2018, 59, 313.	1.0	8
60	Association between serum levels of insulinâ€like growth factorâ€1, bioavailable testosterone, and pathologic Gleason score. Cancer Medicine, 2018, 7, 4170-4180.	1.3	5
61	Factors associated with testosterone recovery after androgen deprivation therapy in patients with prostate cancer. Investigative and Clinical Urology, 2018, 59, 18.	1.0	22
62	Level of invasion into fibromuscular band is an independent factor for positive surgical margin and biochemical recurrence in men with organ confined prostate cancer. BMC Urology, 2018, 18, 7.	0.6	5
63	Image-guided, whole-pelvic, intensity-modulated radiotherapy for biochemical recurrence following radical prostatectomy in high-risk prostate cancer patients. PLoS ONE, 2018, 13, e0190479.	1.1	6
64	Declining incidence of benign lesions among small renal masses treated with surgery: Effect of diagnostic tests for characterization. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 362.e9-362.e15.	0.8	11
65	Selection Criteria for Active Surveillance of Patients with Prostate Cancer in Korea: A Multicenter Analysis of Pathology after Radical Prostatectomy. Cancer Research and Treatment, 2018, 50, 265-274.	1.3	10
66	Comparison of Hand-Assisted Laparoscopic <i>vs</i> Robot-Assisted Laparoscopic <i>vs</i> Partial Nephrectomy in Patients with T1 Renal Masses. Journal of Endourology, 2017, 31, 374-379.	1.1	16
67	Obesity as a Risk Factor for Unfavorable Disease in Men with Low Risk Prostate Cancer and its Relationship with Anatomical Location of Tumor. Journal of Urology, 2017, 198, 71-78.	0.2	10
68	Does Ureteral Catheter Insertion Decrease the Risk of Urinary Leakage After Partial Nephrectomy in Patients With Renal Cell Carcinoma?. Clinical Genitourinary Cancer, 2017, 15, e707-e712.	0.9	5
69	Adaptive functional change of the contralateral kidney after partial nephrectomy. American Journal of Physiology - Renal Physiology, 2017, 313, F192-F198.	1.3	6
70	Fate of newly developed pulmonary embolism after surgery for renal cell carcinoma with vena cava thrombus. International Urology and Nephrology, 2017, 49, 1157-1163.	0.6	10
71	Prognostic Factors for Survival of Patients With Synchronous or Metachronous Brain Metastasis of Renal Cell Carcinoma. Clinical Genitourinary Cancer, 2017, 15, 717-723.	0.9	31
72	Prognostic heterogeneity in T3aNOMO renal cell carcinoma according to the site of invasion. Urologic Oncology: Seminars and Original Investigations, 2017, 35, 458.e17-458.e22.	0.8	24

#	Article	IF	Citations
73	Histologic subtype needs to be considered after partial nephrectomy in patients with pathologic T1a renal cell carcinoma: papillary vs. clear cell renal cell carcinoma. Journal of Cancer Research and Clinical Oncology, 2017, 143, 1845-1851.	1.2	27
74	Heterogeneous oncologic outcomes according to surgical pathology in high-risk prostate cancer: implications for better risk stratification and preoperative prediction of oncologic outcomes. Journal of Cancer Research and Clinical Oncology, 2017, 143, 1871-1878.	1,2	1
75	Conversion to monotherapy with luteinizing-hormone releasing hormone agonist or orchiectomy after reaching PSA nadir following maximal androgen blockade is able to prolong progression-free survival in patients with metastatic prostate cancer: A propensity score matching analysis. Oncology Letters. 2017, 13, 4832-4836.	0.8	0
76	Clinical outcome of high-dose bolus intravenous interleukin-2 with a modified administration schedule for Asian patients with metastatic renal cell carcinoma. Cancer Chemotherapy and Pharmacology, 2017, 79, 173-180.	1,1	1
77	Prognostic value of vascular endothelial growth factor (VEGF), VEGF receptor 2, platelet-derived growth factor- \hat{l}^2 (PDGF- \hat{l}^2), and PDGF- \hat{l}^2 receptor expression in papillary renal cell carcinoma. Human Pathology, 2017, 61, 78-89.	1.1	5
78	Predictors of female genital organ involvement in radical cystectomy for urothelial carcinoma of the bladder: A single-center retrospective analysis of 112 female patients. International Journal of Surgery, 2017, 47, 101-106.	1.1	6
79	Impact of Gleason score on biochemical recurrence in patients with pT3aN0/Nx prostate cancer with positive surgical margins: a multicenter study from the Prostate Cancer Research Committee. Journal of Cancer Research and Clinical Oncology, 2017, 143, 2393-2400.	1.2	5
80	Risk of Intravesical Recurrence After Ureteroscopic Biopsy for Upper Tract Urothelial Carcinoma: Does the Location Matter?. Journal of Endourology, 2017, 31, 259-265.	1,1	31
81	Does lymph node dissection during nephroureterectomy affect oncological outcomes in upper tract urothelial carcinoma patients without suspicious lymph node metastasis on preoperative imaging studies?. World Journal of Urology, 2017, 35, 665-673.	1.2	13
82	Impact of Tumor Location on Local Recurrence After Nephroureterectomy for Upper Tract Urothelial Carcinoma: Implications for Adjuvant Radiotherapy. Clinical Genitourinary Cancer, 2017, 15, e199-e204.	0.9	16
83	Establishment of Korean prostate cancer database by the Korean Urological Oncology Society. Investigative and Clinical Urology, 2017, 58, 434.	1.0	7
84	Preserving Renal Function through Partial Nephrectomy Depends on Tumor Complexity in T1b Renal Tumors. Journal of Korean Medical Science, 2017, 32, 495.	1.1	7
85	Comparison of outcomes between trimodal therapy and radical cystectomy in muscle-invasive bladder cancer: a propensity score matching analysis. Oncotarget, 2017, 8, 68996-69004.	0.8	30
86	Cause of Death in Korean Men with Prostate Cancer: an Analysis of Time Trends in a Nationwide Cohort. Journal of Korean Medical Science, 2016, 31, 1802.	1,1	9
87	Oncological outcomes of patients with incidental pathological T3a stage small renal cell carcinoma after partial nephrectomy. Journal of Cancer Research and Clinical Oncology, 2016, 142, 1651-1657.	1.2	20
88	Impact of metastasectomy on prognosis in patients treated with targeted therapy for metastatic renal cell carcinoma. Journal of Cancer Research and Clinical Oncology, 2016, 142, 2331-2338.	1,2	31
89	Characteristics of Anteriorly Located Prostate Cancer and the Usefulness of Multiparametric Magnetic Resonance Imaging for Diagnosis. Journal of Urology, 2016, 196, 367-373.	0.2	25
90	Differences in the aggressiveness of prostate cancer among Korean, Caucasian, and African American men: A retrospective cohort study of radical prostatectomy. Urologic Oncology: Seminars and Original Investigations, 2016, 34, 3.e9-3.e14.	0.8	40

#	Article	IF	Citations
91	Effect of preoperative urodynamic detrusor overactivity on post-prostatectomy incontinence: a systematic review and meta-analysis. International Urology and Nephrology, 2016, 48, 53-63.	0.6	6
92	Long-term outcomes of tyrosine kinase inhibitor discontinuation in patients with metastatic renal cell carcinoma. Cancer Chemotherapy and Pharmacology, 2016, 77, 339-347.	1.1	4
93	Percutaneous Kidney Biopsy for a Small Renal Mass: A Critical Appraisal of Results. Journal of Urology, 2016, 195, 568-573.	0.2	64
94	Acute Kidney Injury After Radical Cystectomy for Bladder Cancer is Associated with Chronic Kidney Disease and Mortality. Annals of Surgical Oncology, 2016, 23, 686-693.	0.7	21
95	Changing Patterns of Primary Treatment in Korean Men with Prostate Cancer Over 10 Years: A Nationwide Population Based Study. Cancer Research and Treatment, 2016, 48, 899-906.	1.3	30
96	Randomized phase II trial of docetaxel plus prednisolone with or without androgen deprivation treatment in castration-resistant prostate cancer Journal of Clinical Oncology, 2016, 34, 217-217.	0.8	1
97	Is Intravesical Bacillus Calmette-Guérin Therapy Superior to Chemotherapy for Intermediate-risk Non-muscle-invasive Bladder Cancer?: An Ongoing Debate. Journal of Korean Medical Science, 2015, 30, 252.	1.1	4
98	Clinical features and prognosis of prostate cancer with high-grade prostatic intraepithelial neoplasia. Korean Journal of Urology, 2015, 56, 565.	1.2	4
99	KML001 Induces Apoptosis and Autophagic Cell Death in Prostate Cancer Cells via Oxidative Stress Pathway. PLoS ONE, 2015, 10, e0137589.	1.1	14
100	Effects of statin use on the response duration to androgen deprivation therapy in metastatic prostate cancer. Korean Journal of Urology, 2015, 56, 630.	1.2	17
101	Clinicopathological Features of Prostate Ductal Carcinoma: Matching Analysis and Comparison with Prostate Acinar Carcinoma. Journal of Korean Medical Science, 2015, 30, 385.	1.1	24
102	Antibiotic prophylaxis with intravenous ceftriaxone and fluoroquinolone reduces infectious complications after transrectal ultrasound-guided prostatic biopsy. Korean Journal of Urology, 2015, 56, 466.	1.2	7
103	Prognostic impact of preoperative statin use after radical nephroureterectomy for upper urinary tract urothelial carcinoma. Korean Journal of Urology, 2015, 56, 498.	1.2	0
104	Comparative analysis of oncologic outcomes for open vs. robot-assisted radical prostatectomy in high-risk prostate cancer. Korean Journal of Urology, 2015, 56, 572.	1.2	17
105	Randomized clinical trial of a bladder neck plication stitch during robot-assisted radical prostatectomy. Asian Journal of Andrology, 2015, 17, 304.	0.8	16
106	Analysis of pre-operative variables for identifying patients who might benefit from upfront cytoreductive nephrectomy for metastatic renal cell carcinoma in the targeted therapy era. Japanese Journal of Clinical Oncology, 2015, 45, 96-102.	0.6	34
107	Increased Expression of Androgen Receptor mRNA in Human Renal Cell Carcinoma Cells is Associated with Poor Prognosis in Patients with Localized Renal Cell Carcinoma. Journal of Urology, 2015, 194, 1441-1448.	0.2	24
108	Clinicopathological features of $Xp11.2$ translocation renal cell carcinoma. Korean Journal of Urology, $2015, 56, 212$.	1.2	10

#	Article	IF	Citations
109	Prevalence and clinical significance of incidental sup>18F-fluoro-2-deoxyglucose uptake in prostate. Korean Journal of Urology, 2015, 56, 288.	1.2	15
110	Pulmonary Metastasectomy Could Prolong Overall Survival in Select Cases of Metastatic Urinary Tract Cancer. Clinical Genitourinary Cancer, 2015, 13, e297-e304.	0.9	28
111	Kidney Laterality and the Safety of Hand-assisted Live Donor Nephrectomy: Review of 1000 Consecutive Cases at a Single Center. Urology, 2015, 85, 1360-1367.	0.5	11
112	The Therapeutic Effect of Solifenacin Succinate on the Recovery From Voiding Dysfunction After Radical Prostatectomy in Men With Clinically Localized Prostate Cancer: A Prospective, Randomized, Controlled Study. Urology, 2015, 85, 1123-1129.	0.5	17
113	Prevalence of High-grade or Insignificant Prostate Cancer in Korean Men With Prostate-specific Antigen Levels of 3.0-4.0Âng/mL. Urology, 2015, 85, 610-615.	0.5	6
114	Vascular endothelial growth factor receptor tyrosine kinase inhibitor (VEGFR-TKI) rechallenge for patients with metastatic renal cell carcinoma after treatment failure using both VEGFR-TKI and mTOR inhibitor. Cancer Chemotherapy and Pharmacology, 2015, 75, 1025-1035.	1.1	6
115	Hand-assisted laparoscopic bladder cuff excision via the same hand port as that used for nephroureterectomy. World Journal of Urology, 2015, 33, 1459-1465.	1.2	3
116	Adjuvant chemotherapy after radical cystectomy for bladder cancer: a comparative study using inverse-probability-of-treatment weighting. Journal of Cancer Research and Clinical Oncology, 2015, 141, 169-176.	1.2	16
117	Hilar Location is an Independent Prognostic Factor for Recurrence in T1 Renal Cell Carcinoma After Nephrectomy. Annals of Surgical Oncology, 2015, 22, 344-350.	0.7	21
118	Regulatory T cells and TGF- \hat{l}^21 in clinically localized renal cell carcinoma: Comparison with age-matched healthy controls. Urologic Oncology: Seminars and Original Investigations, 2015, 33, 113.e19-113.e25.	0.8	11
119	Oncologic outcomes in men with metastasis to the prostatic anterior fat pad lymph nodes: a multi-institution international study. BMC Urology, 2015, 15, 79.	0.6	10
120	Prognostic significance of platelet-derived growth factor receptor-β expression in localized clear cell renal cell carcinoma. Journal of Cancer Research and Clinical Oncology, 2015, 141, 2213-2220.	1.2	15
121	Statin use after radical prostatectomy reduces biochemical recurrence in men with prostate cancer. Prostate, 2015, 75, 211-217.	1.2	22
122	Predictive role of tissue-based molecular markers in patients treated with sunitinib for metastatic renal cell carcinoma. World Journal of Urology, 2015, 33, 111-118.	1.2	13
123	Prognostic Significance of CREB-Binding Protein and CD81 Expression in Primary High Grade Non-Muscle Invasive Bladder Cancer: Identification of Novel Biomarkers for Bladder Cancer Using Antibody Microarray. PLoS ONE, 2015, 10, e0125405.	1.1	18
124	Overexpression of caldesmon is associated with tumor progression in patients with primary non-muscle-invasive bladder cancer. Oncotarget, 2015, 6, 40370-40384.	0.8	20
125	Prognostic biomarker exploration for patients with metastatic renal cell carcinoma receiving VEGFR TKI Journal of Clinical Oncology, 2015, 33, 491-491.	0.8	0
126	Clinical outcome of patients with metastatic renal cell carcinoma who interrupted VEGFR-TKI after achieving stable disease or better response Journal of Clinical Oncology, 2015, 33, 459-459.	0.8	0

#	Article	IF	Citations
127	Is Bladder Tumor Location Associated with Prostate Cancer Detection after Intravesical Bacillus Calmette-GuÃ@rin Instillation?. PLoS ONE, 2014, 9, e103791.	1.1	4
128	Incidence of Benign Results After Laparoscopic Radical Nephroureterectomy. Journal of the Society of Laparoendoscopic Surgeons, 2014, 18, e2014.00335.	0.5	12
129	Incidence and Dose-volume Analysis of Acute Bladder Toxicity following Pelvic Radiotherapy. Tumori, 2014, 100, 195-200.	0.6	6
130	Long-Term Oncologic Outcomes after Radical Cystectomy for Bladder Cancer at a Single Institution. Journal of Korean Medical Science, 2014, 29, 669.	1.1	6
131	Histologic Variability and Diverse Oncologic Outcomes of Prostate Sarcomas. Korean Journal of Urology, 2014, 55, 797.	1.2	10
132	Prognosis of Prostate Cancer With Other Primary Malignancies. Korean Journal of Urology, 2014, 55, 327.	1.2	3
133	The Type of Nephrectomy Has Little Effect on Overall Survival or Cardiac Events in Patients of 70 Years and Older With Localized Clinical T1 Stage Renal Masses. Korean Journal of Urology, 2014, 55, 446.	1.2	12
134	Predictors of Unfavorable Disease after Radical Prostatectomy in Patients at Low Risk by D'Amico Criteria: Role of Multiparametric Magnetic Resonance Imaging. Journal of Urology, 2014, 192, 402-408.	0.2	23
135	Bone Mineral Density in Prostate Cancer: A Comparative Study of Patients With Prostate Cancer and Healthy Controls Using Propensity Score Matching. Urology, 2014, 83, 385-392.	0.5	4
136	Reassessment of Prognostic Heterogeneity of pT3 Renal Pelvic Urothelial Carcinoma: Analysis in Terms of Proposed pT3 Subclassification Systems. Journal of Urology, 2014, 192, 1064-1071.	0.2	17
137	Peripelvic/periureteral fat invasion is independently associated with worse prognosis in pT3 upper tract urothelial carcinoma. World Journal of Urology, 2014, 32, 157-163.	1.2	24
138	Comparison of oncological outcomes between retropubic radical prostatectomy and robot-assisted radical prostatectomy: an analysis stratified by surgical experience. World Journal of Urology, 2014, 32, 193-199.	1.2	19
139	High percent tumor volume predicts biochemical recurrence after radical prostatectomy in pathological stage <scp>T</scp> 3a prostate cancer with a negative surgical margin. International Journal of Urology, 2014, 21, 484-489.	0.5	9
140	Dihydrotestosterone enhances castration-resistant prostate cancer cell proliferation through STAT5 activation via glucocorticoid receptor pathway. Prostate, 2014, 74, 1240-1248.	1.2	22
141	Efficacy and Safety of Everolimus in Korean Patients with Metastatic Renal Cell Carcinoma Following Treatment Failure with a Vascular Endothelial Growth Factor Receptor-Tyrosine Kinase Inhibitor. Cancer Research and Treatment, 2014, 46, 339-347.	1.3	5
142	Changes of pulmonary function test and development of non-infectious pneumonitis in patients with metastatic renal cell carcinoma treated with everolimus Journal of Clinical Oncology, 2014, 32, 530-530.	0.8	0
143	Active surveillance as a treatment option for metastatic or recurrent renal cell carcinoma Journal of Clinical Oncology, 2014, 32, 426-426.	0.8	0
144	VEGF/VEGFR2 and PDGF-B/PDGFR- \hat{I}^2 expression in non-metastatic renal cell carcinoma: a retrospective study in 1,091 consecutive patients. International Journal of Clinical and Experimental Pathology, 2014, 7, 7681-9.	0.5	13

#	Article	IF	CITATIONS
145	Adjuvant radiotherapy for stage III/IV urothelial carcinoma of the upper tract. Anticancer Research, 2014, 34, 333-8.	0.5	21
146	Changes in the diffusion capacity for carbon monoxide and the development of non-infectious pneumonitis in patients with metastatic renal cell carcinoma treated with everolimus. Anticancer Research, 2014, 34, 5723-8.	0.5	3
147	Prognostic factors of metastatic renal cell carcinoma with extensive sarcomatoid component. Journal of Cancer Research and Clinical Oncology, 2013, 139, 817-827.	1.2	19
148	Tumor volume, surgical margin, and the risk of biochemical recurrence in men with organ-confined prostate cancer. Urologic Oncology: Seminars and Original Investigations, 2013, 31, 168-174.	0.8	26
149	Do molecular biomarkers have prognostic value in primary T1G3 bladder cancer treated with bacillus Calmette-Guerin intravesical therapy?. Urologic Oncology: Seminars and Original Investigations, 2013, 31, 849-856.	0.8	42
150	Preoperative Factors Predictive of Posterolateral Extracapsular Extension After Radical Prostatectomy. Korean Journal of Urology, 2013, 54, 824.	1.2	14
151	Whole pelvic intensity-modulated radiotherapy for high-risk prostate cancer: a preliminary report. Radiation Oncology Journal, 2013, 31, 199.	0.7	14
152	Percent tumor volume predicts biochemical recurrence after radical prostatectomy: multi-institutional data analysis. International Journal of Clinical Oncology, 2012, 17, 355-360.	1.0	20
153	Recent Changes in the Clinicopathologic Features of Korean Men with Prostate Cancer: A Comparison with Western Populations. Yonsei Medical Journal, 2012, 53, 543.	0.9	30
154	Efficacy and safety of vascular endothelial growth factor receptor tyrosine kinase inhibitors in patients with metastatic renal cell carcinoma and poor risk features. Journal of Cancer Research and Clinical Oncology, 2012, 138, 687-693.	1.2	22
155	Reply to Marco Ennas and Alchiede Simonato's Letter to the Editor re: Seong Cheol Kim, Cheryn Song, Wansuk Kim, et al. Factors Determining Functional Outcomes After Radical Prostatectomy: Robot-Assisted Versus Retropubic. Eur Urol 2011;60:413–9. European Urology, 2012, 61, e7.	0.9	1
156	Sorafenib treatment of Asian patients with advanced renal cell carcinoma (RCC) in daily practice: Subset analysis of the large non-interventional PREDICT study Journal of Clinical Oncology, 2012, 30, 4628-4628.	0.8	2
157	Comparison of 2002 TNM nodal status with lymph node density in node-positive patients after radical cystectomy for bladder cancer: Analysis by the number of lymph nodes removed. Urologic Oncology: Seminars and Original Investigations, 2011, 29, 199-204.	0.8	14
158	Outcomes of Single Lymph Node Positive Urothelial Carcinoma After Radical Cystectomy. Journal of Urology, 2011, 185, 2085-2090.	0.2	20
159	Factors Determining Functional Outcomes After Radical Prostatectomy: Robot-Assisted Versus Retropubic. European Urology, 2011, 60, 413-419.	0.9	127
160	Reply from Authors re: Andrew Fuller, Stephen E. Pautler. Additional Evidence for Improved Functional Outcomes Following Robot-Assisted Radical Prostatectomy. Eur Urol 2011;60:420–1. European Urology, 2011, 60, 421-422.	0.9	0
161	Does the greater number of lymph nodes removed during standard lymph node dissection predict better patient survival following radical cystectomy?. World Journal of Urology, 2011, 29, 443-449.	1.2	16
162	Role of Androgen Deprivation Treatment in Patients With Castration-Resistant Prostate Cancer, Receiving Docetaxel-Based Chemotherapy. American Journal of Clinical Oncology: Cancer Clinical Trials, 2011, 34, 140-144.	0.6	15

#	Article	IF	CITATIONS
163	Treatment failure and clinical progression after salvage therapy in men with biochemical recurrence after radical prostatectomy: radiotherapy vs androgen deprivation. BJU International, 2010, 106, 188-193.	1.3	19
164	Urodynamic interpretation of changing bladder function and voiding pattern after radical prostatectomy: a longâ€term followâ€up. BJU International, 2010, 106, 681-686.	1.3	56
165	The Efficacy and Safety of Sunitinib in Korean Patients with Advanced Renal Cell Carcinoma: High Incidence of Toxicity Leads to Frequent Dose Reduction. Japanese Journal of Clinical Oncology, 2010, 40, 980-985.	0.6	86
166	Diffusion-Weighted Magnetic Resonance Imaging in Patients With Unilateral Prostate Cancer on Extended Prostate Biopsy: Predictive Accuracy of Laterality and Implications for Hemi-Ablative Therapy. Journal of Urology, 2010, 184, 1963-1970.	0.2	17
167	Analysis of the Clinicopathologic Characteristics of Men with Prostate Cancer Undergoing Radical Prostatectomy in the Prostate-Specific Antigen Range of Less than 4 ng/ml. Korean Journal of Urology, 2009, 50, 320.	1.2	3
168	Predictive Factors for Upgrading or Upstaging in Biopsy Gleason Score 6 Prostate Cancer. Korean Journal of Urology, 2009, 50, 836.	1.2	5
169	Prognostic significance of non-papillary tumor morphology as a predictor of cancer progression and survival in patients with primary T1G3 bladder cancer. World Journal of Urology, 2009, 27, 277-283.	1.2	25
170	The Protective Role of Renal Parenchyma as a Barrier to Local Tumor Spread of Upper Tract Transitional Cell Carcinoma and its Impact on Patient Survival. Journal of Urology, 2009, 182, 894-899.	0.2	68
171	Factors Influencing Renal Function Reduction After Partial Nephrectomy. Journal of Urology, 2009, 181, 48-54.	0.2	125
172	Predictors of Bladder Tumor Recurrence after Curative Surgery for Upper Urinary Tract Transitional Cell Carcinoma. Korean Journal of Urology, 2009, 50, 635.	1.2	3
173	Analysis of Clinical Features of Patients with Metastatic Spinal Cord Compression Caused by Prostate Cancer. Korean Journal of Urology, 2009, 50, 1174.	1.2	0
174	Mass Screening for Prostate Cancer in Korea: A Population Based Study. Journal of Urology, 2008, 180, 1949-1953.	0.2	17
175	The Analysis of Prognostic Factors of Survival for Patients with Renal Cell Carcinoma according to Lymph Node Involvement or Metastasis. Korean Journal of Urology, 2008, 49, 490.	0.2	1
176	The Preoperative Risk Factors that Influence the Postoperative Renal Function in Living Donor Nephrectomy: The Impact of Dominant Kidney Nephrectomy. Korean Journal of Urology, 2008, 49, 37.	0.2	2
177	Effectiveness of Adjuvant Chemotherapy in Transitional Cell Carcinoma of the Urinary Bladder with Lymph Node Involvement and/or Lymphovascular Invasion Treated by Radical Cystectomy. Urology, 2007, 70, 257-262.	0.5	38
178	Relationship Between the Integrity of the Pelvic Floor Muscles and Early Recovery of Continence After Radical Prostatectomy. Journal of Urology, 2007, 178, 208-211.	0.2	94
179	Comparison of Treatment Outcomes between Photoselective Vaporization and Transurethral Resection of the Prostate for Benign Prostatic Hyperplasia. Korean Journal of Urology, 2007, 48, 297.	0.2	8
180	Comparison of the Surgical Outcome and Renal Function between Radical and Nephron-sparing Surgery for Renal Cell Carcinomas. Korean Journal of Urology, 2007, 48, 671.	0.2	17

#	Article	IF	CITATIONS
181	Clinico-pathological Characteristics of Prostate Cancer in Korean Men and Nomograms for the Prediction of the Pathological Stage of the Clinically Localized Prostate Cancer: A Multi-institutional Update. Korean Journal of Urology, 2007, 48, 125.	0.2	12
182	The Effect of Neoadjuvant Hormonal Treatment in Prostate Cancer on Biochemical Recurrence. Korean Journal of Urology, 2007, 48, 1125.	0.2	1
183	Continuing Trends of the Clinical Parameter Migration in Patients with Prostate Cancer in Korea. Korean Journal of Urology, 2007, 48, 574.	0.2	9
184	The Effectiveness of Simultaneous Renal Artery-vein Clamping during Laparoscopic Partial Nephrectomy on the Surgical Outcome. Korean Journal of Urology, 2007, 48, 897.	0.2	5
185	Impact of Vesico-ureteral Reflux on Renal Function after a Radical Cystectomy: a Comparison of Refluxing and Antirefluxing Orthotopic Bladder Substitutes. Korean Journal of Urology, 2007, 48, 933.	0.2	1
186	Renal Function after Partial Nephrectomy for Renal Cell Carcinoma in Solitary Kidney. Korean Journal of Urology, 2007, 48, 1213.	0.2	3
187	Transforming growth factor- \hat{l}^2 downregulates interleukin-2-induced phosphorylation of signal transducer and activator of transcription 5 in human renal cell carcinoma. Journal of Cancer Research and Clinical Oncology, 2007, 133, 487-492.	1.2	6
188	Prostate cancer in Korean men exhibits poor differentiation and is adversely related to prognosis after radical prostatectomy. Urology, 2006, 68, 820-824.	0.5	68
189	The Anatomic Distribution and Pathological Characteristics of Prostate Cancer: A Mapping Analysis. Korean Journal of Urology, 2006, 47, 578.	0.2	5
190	Prognostic Significance of the Presence of Proper Muscle in the Resected Specimens of Primary T1G3 Bladder Cancer. Korean Journal of Urology, 2006, 47, 137.	0.2	1
191	Korean Nomogram for the Prediction of Recurrence-free Survival after Definitive Surgery for Renal Cell Carcinoma. Korean Journal of Urology, 2006, 47, 963.	0.2	0
192	Prognostic value of lymphovascular invasion in transitional cell carcinoma of upper urinary tract. Urology, 2005, 65, 692-696.	0.5	56
193	The Impact of Tumor Location on Prognosis of Transitional Cell Carcinoma of the Upper Urinary Tract. Journal of Urology, 2004, 171, 621-625.	0.2	164
194	Stromal cells of the human prostate: Initial isolation and characterization., 1996, 28, 89-97.		94